Ask about this productRelated genes to: PVRL2 antibody
- Gene:
- NECTIN2 NIH gene
- Name:
- nectin cell adhesion molecule 2
- Previous symbol:
- HVEB, PVRL2
- Synonyms:
- PVRR2, PRR2, CD112
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 1999-11-15
- Date modifiied:
- 2016-02-12
Related products to: PVRL2 antibody
Related articles to: PVRL2 antibody
- Patients with pathologically high-risk, HPV-negative HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). As CRT can upregulate PD-1/L1 immune checkpoints, adding pembrolizumab may reverse treatment-induced immunosuppression. NRG-HN003 was a phase I trial assessing the safety and recommended phase II schedule of adjuvant pembrolizumab with CRT. Here, we report exploratory immune and genomic correlates of disease-free survival (DFS). - Source: PubMed
Publication date: 2026/06/25
Vujanovic LazarTorres-Saavedra PedroTu FeiUppaluri RavindraYao MinChen JosephineJordan RichardGeiger Jessica LJujjavarapu SrinivasChakravarti ArnabPhan MinhSiddiqui FarzanKulkarni AditiUpadhyay PragatiIsett Brian RobertSica Gabriel LReeder CarlyBao RiyueChen JieJoy MarionFreeman TannerHarris JonathanLe Quynh-ThuBauman Julie EFerris Robert L - Brain metastases (BrM) remain a major cause of mortality in breast cancer (BC), yet the spatial organization and molecular circuitry of the metastatic immune microenvironment are poorly defined. - Source: PubMed
Publication date: 2026/06/24
Zhu JialeYe JunjieMa YulinLin ZhirongWen YupengSheng JianpengYang Mei - Elevated cholesterol levels are associated with the risk of the most socially significant cardiovascular diseases, such as atherosclerosis, ischemic heart disease, and myocardial infarction. - Source: PubMed
Publication date: 2026/06/02
Mamchur AleksandraBruttan MariaDaniel VeronikaKashtanova DariaZelenova ElenaDzhumaniiazova IrinaIvanov MikhailMatkava LorenaBlinova OlgaMitrofanov SergeyGolubnikova LiliyaKumar NaianaMaralova EkaterinaShingaliev AndreyEzhov MaratMeshkov AlekseyChubykina UlianaPogorelova OlgaTripoten MariiaBalahonova TatyanaViskova AlexandraKomarova MadinaGurtsiev TimurGomyranova NataliaVorobeva YuliaHotuleva AnastasiaKolyaskina MariaYudin VladimirMakarov ValentinKeskinov AntonKuzmina LyudmilaBoytsov SergeyYudin SergeySkvortsova Veronika - Acral melanoma (AM), accounting for ~50% of melanomas in Asian populations, exhibits far poorer immunotherapy response (anti-PD-1 ORR < 20%) than cutaneous melanoma (CM, ~43.7%). While the tumor microenvironment (TME) plays a pivotal role in immunotherapy resistance, previous studies mainly focused on immune cells, neglecting stromal components like pericytes-creating a critical knowledge gap in understanding AM's therapeutic refractoriness. - Source: PubMed
Publication date: 2026/05/07
Dong QianZhang YimingHe FuchuSun Aihua - Survival outcomes for pediatric Burkitt lymphoma (BL) substantially vary depending on geography (50-90%), which also serves as a proxy for the prevalence of Epstein-Barr virus (EBV) within the tumors. Although BL is considered an immunologically "cold" tumor with few tumor-infiltrating lymphocytes (TILs), their functional status has not been fully evaluated, especially for EBV-positive disease. Here, we characterize the exhaustion and activation profiles of T cells in the tumor microenvironment (TME) of EBV-positive BL using orthogonal methods, single-cell gene expression analysis, spectral flow cytometry, and immunohistochemistry staining (IHC). We found that CD8+ TILs displayed a mosaic of immune inhibitory gene expression encoding, , , and TIM3. IHC validated the expression of PD1 and TIGIT on CD8+ TILs, as well as their respective ligands, PDL-1, PVR, and Nectin-2 on malignant B cells. Despite exhaustion-associated signatures, CD8+ TILs retain cytotoxic potential, expressing granules (i.e. Granzyme A, Perforin) and cytokines (i.e. IFNγ) and demonstrate an increased uptake of metabolites such as glucose, arginine, and methionine. In peripheral blood, pediatric BL patients exhibited a significantly higher abundance of PD1+TIGIT+ CD8+ T cells compared to healthy children. Notably, these circulating T cells from BL patients express significantly lower levels of TOX, suggesting they are not irreversibly dysfunctional. Together, our results indicate that CD8+ T cells both in the TME and in circulation of children with BL are not terminally exhausted but remain poised for functional re-invigoration. These findings support the potential integration of immune checkpoint inhibitors into combination chemotherapeutic regimens to improve outcomes for these children. - Source: PubMed
Publication date: 2026/04/19
Forconi Catherine SOduor Cliff ISaikumar Priya LRacenet Zachary JFujimori GavinM'Bana ViriatoMatta AngelaMelo JeniLäderach FabienneMaina Titus KOtieno Juliana ADan ChepsirorKibor KibetNjuguna FestusVik TerryKinyua Ann WMünz ChristianBailey Jeffrey AMoormann Ann M